FDA Approves 'Remarkable' Gene-Editing Therapy for Sickle Cell Disease, Posing Challenges for Bluebird Bio

The U.S. Food and Drug Administration (FDA) has approved the world's first gene-edited treatment for sickle cell disease. The treatment, known as CASGEVY or exa-cel, uses CRISPR-Cas9 gene-editing technology to target and "turn off" the genes responsible for sickle cell disease. While it may not cure the disease completely, it has the potential to significantly reduce symptoms and improve the quality of life for eligible patients. The therapy involves a bone marrow transplant and comes with potential limitations and risks, including the need for long-term monitoring and potential adverse effects from chemotherapy. The high cost of the treatment and eligibility restrictions may also pose challenges for widespread access.